Many children receive prophylactic therapy with metered-doseinhalers or oral medications for asthma. Methotrexate (MTX) is the mainstay of therapy for acute lymphoblastic leukemia (ALL), the most common pediatric mali...
详细信息
Many children receive prophylactic therapy with metered-doseinhalers or oral medications for asthma. Methotrexate (MTX) is the mainstay of therapy for acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, but it is also used as a corticosteroid-sparing medication in patients with severe bronchial asthma. A question that arises in children with ALL who also suffer from bronchial asthma is what is the role of MTX against their respiratory disease. MTX in ALL protocols is usually given per os at 20 mg/m~2/week during maintenance, while in severe corticosteroid-dependent asthma 7.5 mg to 20 mg/week are commonly prescribed. Because of the disease and therapy-induced immunosuppresion in children with ALL who receive weekly MTX during maintenance, someone would expect that these children with both ALL and asthma would not need prophylactic treatment with inhaled and/or oral medications. Instead of that children with ALL and bronchial asthma are classified based on the Global Initiative forAsthma criteria based on symptomatology alone, irrespective of their immunosuppressive treatment. In our experience 80% of children with both ALL and asthma needed prophylactic treatment with inhaled corticosteroids with or without long-acting inhaled b_2 agonists or leukotriene receptor antagonists during maintenance therapy of ALL. So far MTX has been used in \"difficult\" asthma in children and proved to be successful in sparing the oral steroid dose in most cases. On the other hand it is important to highlight that the \"difficult\" asthmatic phenotype is probably neutrophilic and not eosinophilic or in some cases its steroid resistance is due to low binding affinity or small number of steroid receptors. Hence, it appears that although the MTX-steroids combination therapy works in difficult asthma, MTX alone is not enough to control their symptoms and that they need prophylactic treatment with other medications for satisfactory control. These results highlight the
作者：
Ando, YNagoya Univ
Sch Med Dept Internal Med 1 Showa Ku Nagoya Aichi 466 Japan
Discusses about a report by researcher Pronk and colleagues regarding a dose escalation study of the combination chemotherapy of docetaxel and ifosfamide. Use of human liver microsomes in vitro studies; Factor that in...
详细信息
Discusses about a report by researcher Pronk and colleagues regarding a dose escalation study of the combination chemotherapy of docetaxel and ifosfamide. Use of human liver microsomes in vitro studies; Factor that inhibits the metabolic activation of ifosfamide; Combination regimens that seem unlikely to cause similar interaction.
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer? D. Tassinari Search for other works by this author on: Oxford Academic PubMed Google Scholar D. Tassinari ...
详细信息
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer? D. Tassinari Search for other works by this author on: Oxford Academic PubMed Google Scholar D. Tassinari V. Arcangeli Search for other works by this author on: Oxford Academic PubMed Google Scholar V. Arcangeli I. Panzini Search for other works by this author on: Oxford Academic PubMed Google Scholar I. Panzini S. Sartori Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Sartori L. Gianni Search for other works by this author on: Oxford Academic PubMed Google Scholar L. Gianni A. Ravaioli Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Ravaioli Annals of Oncology, Volume 11, Issue 8, 1 August 2000, Pages 1071, https://***/10.1023/A:1008347116732 Published: 01 August 2000
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel S. Hofer *E-mail: silviahofer@*** Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Hofer S. Hunzik...
详细信息
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel S. Hofer *E-mail: silviahofer@*** Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Hofer S. Hunziker Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Hunziker L. Tornillo Search for other works by this author on: Oxford Academic PubMed Google Scholar L. Tornillo C. U. Ludwig Search for other works by this author on: Oxford Academic PubMed Google Scholar C. U. Ludwig Annals of Oncology, Volume 14, Issue 2, 1 February 2003, Pages 340, https://***/10.1093/annonc/mdg052 Published: 01 February 2003
暂无评论